Skip to main content
SpringerLink
Log in

LncRNA MEG8 ameliorates Parkinson’s disease neuro-inflammation through miR-485-3p/FBXO45 axis

  • Original article
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

Abstract

Objective

Studies suggest that LncRNA maternally expressed 8, small nucleolar RNA host gene (MEG8) contributes to inflammatory regulation, while the function and potential mechanisms of MEG8 in Parkinson’s disease (PD) are unknown. This study aimed to assess the clinical value and biological function of MEG8 in PD.

Methods

One hundred and two PD patients, eighty-six AD patients, and eighty healthy controls were enrolled in this study. Lipopolysaccharide (LPS)-induced microglia BV2 constructs an in vitro cell model. RT-qPCR was conducted to quantify the levels of MEG8, miR-485-3p, and FBXO45 in serum and cells. ROC curve was employed to examine the diagnostic value of MEG8 in PD. Serum and cellular pro-inflammatory factor secretion were quantified by ELISA. Dual-luciferase reporter and RIP assay to validate the targeting relationship between miR-485-3p and FBXO45.

Results

MEG8 and FBXO45 were significantly decreased in the serum of PD patients and LPS-induced bv2, while miR-485-3p was increased (P < 0.05). ROC curve confirmed that serum MEG8 has high sensitivity and specificity to identify PD patients from healthy controls and AD patients, respectively. Elevated MEG8 alleviated LPS-induced inflammatory factor overproduction compared with LPS-induced BV2 (P < 0.05), but this alleviating effect was eliminated by miR-485-3p (P < 0.05). The LPS-induced inflammatory response was suppressed by the low expression of miR-485-3p but significantly reversed by silencing of FBXO45. MEG8 was a sponge for miR-485-3p and inhibited its levels and promoted FBXO45 expression (P < 0.05).

Conclusion

Elevated MEG8 is a potential diagnostic biomarker for PD and may mitigate inflammatory damage in PD via the miR-485-3p/FBXO45 axis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Availability of data and materials

The data used and analyzed can be obtained from the corresponding author under a reasonable request.

References

  1. Geng X, Zou Y, Li S, Qi R, Yu H, Li J (2023) MALAT1 mediates alpha-synuclein expression through miR-23b-3p to induce autophagic impairment and the inflammatory response in microglia to promote apoptosis in dopaminergic neuronal cells. Mediators Inflamm 2023:4477492

    Article  PubMed  PubMed Central  Google Scholar 

  2. Asadi MR, Abed S, Kouchakali G, Fattahi F, Sabaie H, Moslehian MS et al (2023) Competing endogenous RNA (ceRNA) networks in Parkinson’s disease: a systematic review. Front Cell Neurosci 17:1044634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Varma P, Narayan L, Alty J, Painter V, Padmakumar C (2021) An innovative personalised management program for older adults with Parkinson’s disease: new concepts and future directions. J Pers Med. 11:1

    Article  Google Scholar 

  4. Peng S, Jia J, Sun J, Xie Q, Zhang X, Deng Y et al (2019) LXW7 attenuates inflammation via suppressing Akt/nuclear factor kappa B and mitogen-activated protein kinases signaling pathways in lipopolysaccharide-stimulated BV2 microglial cells. Int Immunopharmacol 77:105963

    Article  CAS  PubMed  Google Scholar 

  5. Kuo MC, Liu SC, Hsu YF, Wu RM (2021) The role of noncoding RNAs in Parkinson’s disease: biomarkers and associations with pathogenic pathways. J Biomed Sci 28(1):78

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Liu L, Zhou T, Li T, Liang Z, Luo X (2022) LncRNA DLX6-AS1 promotes microglial inflammatory response in Parkinson’s disease by regulating the miR-223-3p/NRP1 axis. Behav Brain Res 431:113923

    Article  CAS  PubMed  Google Scholar 

  7. Abrishamdar M, Jalali MS, Rashno M (2022) MALAT1 lncRNA and Parkinson’s disease: the role in the pathophysiology and significance for diagnostic and therapeutic approaches. Mol Neurobiol 59(9):5253–5262

    Article  CAS  PubMed  Google Scholar 

  8. Li K, Wang Z (2023) lncRNA NEAT1: key player in neurodegenerative diseases. Ageing Res Rev 86:101878

    Article  CAS  PubMed  Google Scholar 

  9. Li YZ, Zhu HC, Du Y, Zhao HC, Wang L (2022) Silencing lncRNA SLC16A1-AS1 induced ferroptosis in renal cell carcinoma through miR-143-3p/SLC7A11 signaling. Technol Cancer Res Treat 21:15330338221077804

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lin X, Wang R, Li R, Tao T, Zhang D, Qi Y (2022) Diagnostic performance of miR-485-3p in patients with Parkinson’s disease and its relationship with neuroinflammation. Neuromolecular Med 24(2):195–201

    Article  CAS  PubMed  Google Scholar 

  11. Xie W, Jiang L, Huang X, Shang H, Gao M, You W et al (2021) lncRNA MEG8 is downregulated in osteoarthritis and regulates chondrocyte cell proliferation, apoptosis and inflammation. Exp Ther Med 22(4):1153

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Xu D, Dai R, Chi H, Ge W, Rong J (2021) Long non-coding RNA MEG8 suppresses hypoxia-induced excessive proliferation, migration and inflammation of vascular smooth muscle cells by regulation of the miR-195-5p/RECK axis. Front Mol Biosci 8:697273

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Buccarelli M, Lulli V, Giuliani A, Signore M, Martini M, D’Alessandris QG et al (2020) Deregulated expression of the imprinted DLK1-DIO3 region in glioblastoma stemlike cells: tumor suppressor role of lncRNA MEG3. Neuro Oncol 22(12):1771–1784

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Tan MC, Widagdo J, Chau YQ, Zhu T, Wong JJ, Cheung A et al (2017) The activity-induced long non-coding RNA Meg3 modulates AMPA receptor surface expression in primary cortical neurons. Front Cell Neurosci 11:124

    Article  PubMed  PubMed Central  Google Scholar 

  15. Zhao XY, Lu MH, Yuan DJ, Xu DE, Yao PP, Ji WL et al (2019) Mitochondrial dysfunction in neural injury. Front Neurosci 13:30

    Article  PubMed  PubMed Central  Google Scholar 

  16. Sui S, Sun L, Zhang W, Li J, Han J, Zheng J et al (2021) LncRNA MEG8 attenuates cerebral ischemia after ischemic stroke through targeting miR-130a-5p/VEGFA signaling. Cell Mol Neurobiol 41(6):1311–1324

    Article  CAS  PubMed  Google Scholar 

  17. Zheng Y, Sun S, Yu M, Fu X (2019) Identification of potential hub-lncRNAs in ischemic stroke based on Subpathway-LNCE method. J Cell Biochem 120(8):12832–12842

    Article  CAS  PubMed  Google Scholar 

  18. Daniel SE, Lees AJ (1993) Parkinson’s disease society brain bank, London: overview and research. J Neural Transm Suppl 39:165–172

    CAS  PubMed  Google Scholar 

  19. Zhang J, Yang Y, Zhou C, Zhu R, Xiao X, Zhou B et al (2022) LncRNA miR-17-92a-1 cluster host gene (MIR17HG) promotes neuronal damage and microglial activation by targeting the microRNA-153-3p/alpha-synuclein axis in Parkinson’s disease. Bioengineered 13(2):4493–4516

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zhu Z, Huang P, Sun R, Li X, Li W, Gong W (2022) A Novel long-noncoding RNA LncZFAS1 prevents MPP(+)-induced neuroinflammation through MIB1 activation. Mol Neurobiol 59(2):778–799

    Article  CAS  PubMed  Google Scholar 

  21. Zhu HB, Li B, Guo J, Miao YZ, Shen YT, Zhang YZ et al (2021) LncRNA MEG8 promotes TNF-alpha expression by sponging miR-454-3p in bone-invasive pituitary adenomas. Aging (Albany NY) 13(10):14342–14354

    Article  CAS  PubMed  Google Scholar 

  22. Tolosa E, Garrido A, Scholz SW, Poewe W (2021) Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol 20(5):385–397

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lotankar S, Prabhavalkar KS, Bhatt LK (2017) Biomarkers for Parkinson’s disease: recent advancement. Neurosci Bull 33(5):585–597

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Zhou Y, Zhao Z, Yan L, Yang J (2021) MiR-485-3p promotes proliferation of osteoarthritis chondrocytes and inhibits apoptosis via Notch2 and the NF-kappaB pathway. Immunopharmacol Immunotoxicol 43(3):370–379

    Article  CAS  PubMed  Google Scholar 

  25. Sole C, Domingo S, Ferrer B, Moline T, Ordi-Ros J, Cortes-Hernandez J (2019) MicroRNA expression profiling identifies miR-31 and miR-485-3p as regulators in the pathogenesis of discoid cutaneous lupus. J Invest Dermatol 139(1):51–61

    Article  CAS  PubMed  Google Scholar 

  26. Koh HS, Lee S, Lee HJ, Min JW, Iwatsubo T, Teunissen CE et al (2021) Targeting microRNA-485-3p blocks Alzheimer’s disease progression. Int J Mol Sci 22(23):13136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Tsai M, Osman W, Adair J, ElMergawy R, Chafin L, Johns F et al (2022) The E3 ligase subunit FBXO45 binds the interferon-lambda receptor and promotes its degradation during influenza virus infection. J Biol Chem 298(12):102698

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Saiga T, Fukuda T, Matsumoto M, Tada H, Okano HJ, Okano H et al (2009) Fbxo45 forms a novel ubiquitin ligase complex and is required for neuronal development. Mol Cell Biol 29(13):3529–3543

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Tada H, Okano HJ, Takagi H, Shibata S, Yao I, Matsumoto M et al (2010) Fbxo45, a novel ubiquitin ligase, regulates synaptic activity. J Biol Chem 285(6):3840–3849

    Article  CAS  PubMed  Google Scholar 

  30. Na Y, Calvo-Jimenez E, Kon E, Cao H, Jossin Y, Cooper JA (2020) Fbxo45 binds SPRY motifs in the extracellular domain of N-cadherin and regulates neuron migration during brain development. Mol Cell Biol 40(14):e00539-e619

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Cao T, Cui Y, Wang Y, Wu L, Yu K, Chen K et al (2022) CACNA1C-AS2 inhibits cell proliferation and suppresses cell migration and invasion via targeting FBXO45 and PI3K/AKT/mTOR pathways in glioma. Apoptosis 27(11–12):979–991

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This study was funded by the Taizhou Social Development Science and Technology Plan Project (22ywb37).

Author information

Authors and Affiliations

  1. Department of Neurology, Taizhou Central Hospital (Taizhou University Hospital), No.999, Donghai Avenue, Jiaojiang District, Taizhou, 318000, Zhejiang, China

    Xia Lin, Taotao Tao, Xinwei He, Lingqun Mao, Luping Pan & Linkao Chen

Authors
  1. Xia Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taotao Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xinwei He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lingqun Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luping Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Linkao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XL carried out the research design and conception; TT and XH analyzed and interpreted the data regarding; LM performed the examination of sample; LP and TT contributed essential reagents or tools; XL and LC authors wrote and revised the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Linkao Chen.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Ethics approval and consent to participate

The experimental procedures were all in accordance with the guideline of the Ethics Committee of Taizhou Central Hospital (Taizhou University Hospital) and has approved by the Ethics Committee of Taizhou Central Hospital (Taizhou University Hospital). This study complies with the Declaration of Helsinki. A signed written informed consent was obtained from each patient.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (TIF 942 KB)

Supplementary file2 (TIF 3289 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, X., Tao, T., He, X. et al. LncRNA MEG8 ameliorates Parkinson’s disease neuro-inflammation through miR-485-3p/FBXO45 axis. Acta Neurol Belg 124, 549–557 (2024). https://doi.org/10.1007/s13760-023-02388-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13760-023-02388-7

Keywords

Search

Navigation